Thermo Fisher Scientific, Inc. provided earnings guidance for the full year of 2013. The company is planning for the global economic environment to remain challenging. The company is initiating adjusted EPS and revenue guidance for the full year 2013.

The company expects to achieve adjusted EPS in the range of $5.32 to $5.46 for 2013, which would result in 8% to 11% adjusted EPS growth over 2012. The company expects to achieve 2013 revenue in the range of $12.80 billion to $13.00 billion, for 2% to 4% revenue growth year over year. The company expects net interest expense to be up about $20 million to $25 million year-over-year, reflecting the full year interest cost of the debt issued to fund the One Lambda acquisition.

The company is forecasting adjusted income tax rate to be in the range of 14.5% to 15% down from 16.7% in 2012 primarily as a result of the double benefit on the R&D tax credit and tax synergies related to the acquisitions and ongoing tax planning benefits. Capital expenditures to be in the range of $300 million to $325 million and free cash flow to be in the range of $1.8 billion to $1.9 billion.